The Ever-Changing Hard Surface Disinfectant Landscape in COVID-19 times

The Ever-Changing Hard Surface Disinfectant Landscape in COVID-19 times

Published on April 14, 2020

Author: Teri Dickinson, Manager, Regulatory Affairs, Dell Tech Laboratories Ltd.

These days, the world of hard surface disinfectants and pathway to registration changes almost weekly.  With the health and safety of Canadians being at the fore front the quick access to disinfectant products has been a top priority. 

Health Canada has implemented interim measures to expedite access to disinfectants to address product shortages and published a list of hard-surface disinfectants that are likely to be effective for use against coronavirus (COVID-19).

Want your product to be on the list?  Want to make indirect efficacy claims for SARS-CoV-2, the virus that causes COVID-19? Your product will need to be reviewed and approved with one or more of the following:

  • labelled as a broad-spectrum virucide, that is supported by an efficacy claim against any of:
    •    Adenovirus type 5
    •    Bovine Parovirus
    •    Canine Parvovirus
    •    Poliovirus type 1
  • carry a specific claim against non-enveloped viruses of the picornaviridae, caliciviridae, astroviridae, reoviridae, or papillomaviridae families or
  • carry a specific claim against a specific coronavirus, such as
    •    MERS-CoV
    •    SARS-CoV
    •    human coronavirus strain 229E

References:

Hard-surface disinfectants and hand sanitizers (COVID-19): List of hard-surface disinfectants 

https://www.canada.ca/en/health-canada/services/drugs-health-products/disinfectants/covid-19/list.html

 

 

Related Articles

Value-Based Drug Pricing in Canada and its Limitations

Value-Based Drug Pricing in Canada and its Limitations

Drug pricing is a complex and controversial issue that often sparks debates among patients, pharmaceutical companies, and the government. Prices can vary significantly...

Addressing Underrepresentation in Clinical Trials: FDA's Diversity Action Plan

Addressing Underrepresentation in Clinical Trials: FDA's Diversity Action Plan

The U.S. Food and Drug Administration (FDA) released a new draft guidance in June 2024 to enhance the diversity of clinical trial participants. The guidance details the...

VIRTUAL HEALTHCARE IN CANADA

VIRTUAL HEALTHCARE IN CANADA

“Virtual care” is defined as any “interaction between patients and/or members of their circle of care, occurring remotely, using any forms of communication or...